Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.
Kristin G AndersonShannon K OdaBreanna M BatesMadison G BurnettMagdalia Rodgers SuarezSusan L RuskinPhilip D GreenbergPublished in: Journal for immunotherapy of cancer (2022)
As many ovarian tumors overexpress FasL, an IFP that converts the Fas-mediated death signal into pro-survival and proliferative signals may be used to enhance engineered adoptive T cell therapy for patients.